Mokdad, A. H., Forouzanfar, M. H., Daoud, F., Mokdad, A. A., El Bcheraoui, C., Moradi-Lakeh, M., Degenhardt, L., & Murray, C. J. L. (2016). Global burden of diseases, injuries, and risk factors for young people’s health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 387(10036), 2383–2401. doi: 10.1016/S0140-6736(16)00648-6

Moran, P., Romaniuk, H., Coffey, C., Chanen, A., Degenhardt, L., Borschmann, R., & Patton, G. (2016). The influence of personality disorder on the future mental health and social adjustment of young adults: a population-based cohort study. The Lancet Psychiatry, 3(7), 636-645. doi: 10.1016/S2215-0366(16)30029-3

Nair, N. K., Newton, N. C., Barrett, E. L., Slade, T., Conrod, P. J., Baillie, A. J., Champion, K. E., & Teesson, M. (2016). Personality and early adolescent alcohol use: assessing the four factor model of vulnerability. Journal of Addiction Prevention, 4(2), 6. Retrieved from http://www.avensonline.org/wp-content/uploads/JAP-2330-2178-04-0029.pdf.

Nelson, E. C., Agrawal, A., Heath, A. C., Bogdan, R., Sherva, R., Zhang, B., Al-Hasani, R., Bruchas, M. R., Chou, Y., Demers, C. H., Carey, C. E., Conley, E. D., Fakira, A. K., Farrer, L. A., Goate, A., Gordon, S., Henders, A. K., Hesselbrock, V., Kapoor, M., Lynskey, M. T., Madden, P. A. F., Moron, J. A., Rice, J. P., Saccone, N. L., Schwab, S. G., Shand, F. L., Todorov, A. A., Wallace, L., Wang, T., Wray, N. R., Zhou, X., Degenhardt, L., Martin, N. G., Hariri, A. R., Kranzler, H. R., Gelernter, J., Bierut, L. J., Clark, D. J., & Montgomery, G. W. (2016). Evidence of CNIH3 involvement in opioid dependence. Molecular Psychiatry, 21(5), 608-614. doi:10.1038/mp.2015.102

Newton, N. C., Conrod, P. J., Slade, T., Carragher, N., Champion, K. E., Barrett, E. L., Kelly, E. V., Nair, N. K., Stapinski, L., & Teesson, M. (2016). The long-term effectiveness of a selective, personality-targeted prevention program in reducing alcohol use and related harms: a cluster randomized controlled trial. Journal of Child Psychology and Psychiatry, 57(9), 1056-1065. doi: 10.1111/jcpp.12558

Newton, N. C., Teesson, M., Stapinski, L., Perry, Y., Shand, F., & Christensen, H. (2016). Innovative approaches to preventing and reducing substance use and mental health problems. In R. G. Menzies, M. Kyrios & N. Kazantzis (Eds.), Innovations and future directions in the behavioural and cognitive therapies (pp. 39-43). Samford Valley, Qld: Australian Academic Press.

Nielsen, S., & Van Hout, M. C. (2016). Over-the-counter codeine - from therapeutic use to dependence and the grey areas in between. In Current Topics in Behavioral Neurosciences (pp. 1-17). Berlin: Springer.

Nielsen, S., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L., Demirkol, A., Muhleisen, P., & Lintzeris, N. (2016). Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. Drug and Alcohol Review, 35(1), 70-75. doi: 10.1111/dar.12315

Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews, 5, Art. No.: CD011117. doi: 10.1002/14651858.CD011117.pub2

Noori, R., Farhoudian, A., Naranjiha, H., Farhadi, M. H., Dolan, K., & Khoddami-Vishteh, H. (2016). Comparison of characteristics of methamphetamine versus opiate users in Tehran, Iran. International Journal of High Risk Behaviors and Addiction, 5(4). doi: 10.5812/ijhrba.28815

Palamar, J. J., & Barratt, M. J. (2016). Synthetic cannabinoids: undesirable alternatives to natural marijuana. American Journal of Drug and Alcohol Abuse, 42(4), 371-373. doi: 10.3109/00952990.2016.1139584

Patel, V., Chisholm, D., Parikh, R., Charlson, F. J., Degenhardt, L., Dua, T., Ferrari, A. J., Hyman, S., Laxminarayan, R., Levin, C., Lund, C., Medina Mora, M. E., Petersen, I., Scott, J., Shidhaye, R., Vijayakumar, L., Thornicroft, G., & Whiteford, H. (2016). Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. The Lancet, 387(10028), 1672-1685. doi: 10.1016/S0140-6736(15)00390-6